The first and only FDA-approved microbiota-based
therapeutic in oral capsules to prevent C. diff
recurrence following antibacterial treatment1
Limitation of Use: VOWST is not indicated for treatment of CDI
VOWST HELPED PREVENT
SUBSEQUENT C. DIFF RECURRENCE
Significantly reduced C. diff recurrence at 8 weeks
compared to placebo following standard-of-care antibacterials in the ECOSPOR III clinical trial1,2
Primary endpoint - rate of recurrence was significantly lower in
VOWST recipients compared to placebo (12% vs. 40%, respectively),
a 0.32 relative risk (95% confidence interval, 0.18, 0.58; P<0.001)1,2
(vs. 60% of participants
receiving placebo)1,2
Recurrence-free response through 24 weeks — secondary endpoint1,3
(vs. 53% of participants
receiving placebo)1,3*
ECOSPOR III was a Phase 3, multicenter, double-blind, randomized, placebo-controlled trial evaluating C. diff recurrence at 8 weeks; secondary endpoints at 4, 12, 24 weeks. In the intent-to-treat population, participants received VOWST or placebo after standard-of-care antibacterial treatment (vancomycin/fidaxomicin) and laxative. Those lost to follow-up, terminated prematurely, or died prior to end of study time interval counted as a recurrence. Data were rounded to the nearest whole number for presentation.
Safety profile of VOWST through 8 weeks1
The majority of adverse reactions were mild
or moderate in severity1
The most common adverse reactions (reported in ≥5% of participants) were abdominal distension (31%), fatigue (22%), constipation (14%), chills (11%), and diarrhea (10%)1
No serious adverse events were considered related to the use of VOWST1
Consider prescribing VOWST and antibacterials at the same time to help ensure patients get access to VOWST at the time of completing antibacterials
Why C. diff can keep
coming back
Antibacterials can leave
patients at risk of recurrence
Oral VOWST
dosing
4 capsules taken orally once daily over 3 consecutive days
Get information about VOWST Voyage™
Helping your patients
access their VOWST treatment
REFERENCES: 1. VOWST [Prescribing Information]. Cambridge, MA: Seres Therapeutics, Inc. and Nestlé Health Science. 04/2023. 2. Feuerstadt P, Louie TJ, Lashner B, et al. N Engl J Med. 2022;236:220-229. doi:10.1056/NEJMoa2106516. 3. Cohen SH, Louie TJ, Sims M, et al. JAMA. Published Online: October 19, 2022. doi:10.1001/jama.2022.16476.
